The present invention covers formulations of Oxcarbazepine coated tablets, as well as the processes to manufacture those formulations of immediate or modified release. The formulations of the present invention present high bioavailability and low prevalence of side effects, using the active ingredient co-micronized Oxcarbazepine in a range improving the intestinal absorption of the modulated form, it means, reducing the adverse effects to the patients, not causing any damages to the crystalline structure of this active ingredient by co-micronization in the range of 15 to 40 microns of average particle size with the support of soluble co-micronizing agents.
